Please ensure Javascript is enabled for purposes of website accessibility

Wall Street Backs the Wrong Biotech

By Dave Williamson - Apr 12, 2013 at 10:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are these Wall Street upgrades really deserved?

In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen (BIIB 1.37%) and its new BG12 drug for multiple sclerosis. However, David favors Gilead (GILD -0.57%) over Biogen since Gilead has a larger, more diverse product pipeline. Celgene (CELG) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen (AMGN 0.07%) is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
Biogen Inc. Stock Quote
Biogen Inc.
$205.13 (1.37%) $2.77
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$64.64 (-0.57%) $0.37
Amgen Inc. Stock Quote
Amgen Inc.
$253.19 (0.07%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.